Carmignac Gestion Buys New Shares in Bristol Myers Squibb Company $BMY

Carmignac Gestion purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,014 shares of the biopharmaceutical company’s stock, valued at approximately $519,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $27,000. Bayban acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $31,000. Finally, Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on BMY. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a report on Friday, July 31st. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “strong-buy” rating for the company. Finally, Bank of America cut their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Stock Down 3.3%

BMY traded down $2.19 on Tuesday, reaching $64.63. The company’s stock had a trading volume of 9,522,716 shares, compared to its average volume of 11,932,380. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The business’s 50 day moving average is $63.23 and its 200 day moving average is $60.00. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock has a market cap of $132.02 billion, a price-to-earnings ratio of 14.24, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.